WA
ICPT

WFG Advisors’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

WFG Advisors’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$108K Buy
888
+125
+16% +$14.5K 0.02% 511
2017
Q1 		$86K Sell
763
-275
-26% -$32.1K 0.02% 523
2016
Q4 		$113K Buy
1,038
+43
+4% +$5.12K 0.03% 495
2016
Q3 		$164K Buy
+995
New +$157K 0.04% 411
2015
Q1 		– Sell
-125
Closed -$20K – 2121
2014
Q4 		$20K Buy
+125
New +$23.1K ﹤0.01% 1227

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

WFG Advisors's ICPT Position: Q2 2017 in Review

WFG Advisors increased its Intercept Pharmaceuticals, Inc. (ICPT) stake by 16% in Q2 2017, buying an estimated $14.5K and bringing the position to 888 shares worth $108K. The position accounts for 0.02% of the portfolio, ranked #511.

WFG Advisors first reported a position in ICPT in Q4 2014 and has held it in 5 quarters since. The position peaked at $164K in Q3 2016. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2017.

  • WFG Advisors held 888 shares of Intercept Pharmaceuticals, Inc. worth $108K as of Q2 2017.
  • WFG Advisors bought 125 Intercept Pharmaceuticals, Inc. shares in Q2 2017, an estimated $14.5K.
  • Intercept Pharmaceuticals, Inc. made up 0.02% of WFG Advisors's portfolio in Q2 2017, its #511 holding.
  • WFG Advisors first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2014 and has held it in 5 quarters since.
  • WFG Advisors's Intercept Pharmaceuticals, Inc. position peaked at $164K in Q3 2016.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.